Tissue Regenix, a regenerative medical devices company, has appointed Steve Couldwell as chief executive officer of the group, effective immediately.
Couldwell has been a non- executive director since July 2013.
He has over 25 years' experience in the pharmaceutical and medical device industry and was most recently chief operating officer for Global Sanofi Biosurgery.
Prior to this he held a number of roles at Smith & Nephew including president, orthopaedics, Europe and senior VP sales and marketing of the advanced wound management business.
At 9:06am: (LON:TRX) Tissue Regenix Group PLC share price was 0p at 8.63p